DDInter596 DDInter1492
Doxorubicin is a cytotoxic anthracycline antibiotic isolated from cultures of Streptomyces peucetius var. caesius along side with daunorubicin, another cytotoxic agent, in 1970.[A1575,A257709,A257614] Although they both have aglyconic and sugar moieties, doxorubicin's side chain terminates with a primary alcohol group compared to the methyl group of daunorubicin. Although its detailed molecular mechanisms have yet to be understood, doxorubicin is generally thought to exert its effect through DNA intercalation, which eventually leads to DNA damage and the generation of reactive oxygen species. Thanks to its efficacy and broad effect, doxorubicin was approved by the FDA in 1974 to treat a variety of cancer, including but not limited to breast, lung, gastric, ovarian, thyroid, non-Hodgkin’s and Hodgkin’s lymphoma, multiple myel
Ponatinib is a novel Bcr-Abl tyrosine kinase inhibitor that is especially effective against the T315I mutation for the treatment of chronic myeloid leukemia. FDA approved on December 14, 2012.
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB11
ABCB11 {u} (Gene) is bound by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) ABL1
ABL1 {u} (Gene) is bound by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) TRAPPC6A
TRAPPC6A {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) AARS
AARS {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) downregulates {v} (Gene) OXA1L
OXA1L {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) DRAP1
DRAP1 {u} (Gene) is downregulated by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) causes {v} (Side Effect) Migraine
Migraine {u} (Side Effect) is caused by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) resembles {v} (Compound) Daunorubicin
Daunorubicin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Ponatinib
Doxorubicin {u} (Compound) upregulates {v} (Gene) FGFR2
FGFR2 {u} (Gene) is bound by {v} (Compound) and {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Doxorubicin {u} (Compound) binds {v} (Gene) ABCB11
ABCB11 {u} (Gene) is bound by {v} (Compound) Cimetidine
Cimetidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ponatinib
Doxorubicin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Ponatinib (Compound)
Doxorubicin (Compound) downregulates ABL1 (Gene) and ABL1 (Gene) is bound by Ponatinib (Compound)
Doxorubicin (Compound) upregulates TRAPPC6A (Gene) and TRAPPC6A (Gene) is upregulated by Ponatinib (Compound)
Doxorubicin (Compound) downregulates AARS (Gene) and AARS (Gene) is upregulated by Ponatinib (Compound)
Doxorubicin (Compound) downregulates OXA1L (Gene) and OXA1L (Gene) is downregulated by Ponatinib (Compound)
Doxorubicin (Compound) upregulates DRAP1 (Gene) and DRAP1 (Gene) is downregulated by Ponatinib (Compound)
Doxorubicin (Compound) causes Migraine (Side Effect) and Migraine (Side Effect) is caused by Ponatinib (Compound)
Doxorubicin (Compound) resembles Daunorubicin (Compound) and Daunorubicin may cause a moderate interaction that could exacerbate diseases when taken with Ponatinib
Doxorubicin (Compound) upregulates FGFR2 (Gene) and FGFR2 (Gene) is bound by Ponatinib (Compound) and FGFR2 (Gene) is upregulated by Ponatinib (Compound)
Doxorubicin (Compound) binds ABCB11 (Gene) and ABCB11 (Gene) is bound by Cimetidine (Compound) and Cimetidine may cause a minor interaction that can limit clinical effects when taken with Ponatinib